PT - JOURNAL ARTICLE AU - Boehme, Karl W. AU - Kennedy, Joshua L. AU - Snowden, Jessica AU - Owens, Shana M. AU - Kouassi, Marianne AU - Mann, Ryan L. AU - Paredes, Amairani AU - Putt, Claire AU - James, Laura AU - Jin, Jing AU - Du, Ruofei AU - Kirkpatrick, Catherine AU - Modi, Zeel AU - Caid, Katherine AU - Zohoori, Namvar AU - Kothari, Atul AU - Boyanton, Bobby L. AU - Forrest, J. Craig TI - Pediatric SARS-CoV-2 seroprevalence in Arkansas over the first year of the COVID-19 pandemic AID - 10.1101/2021.08.04.21261592 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.04.21261592 4099 - http://medrxiv.org/content/early/2021/08/15/2021.08.04.21261592.short 4100 - http://medrxiv.org/content/early/2021/08/15/2021.08.04.21261592.full AB - Background SARS-CoV-2 seroprevalence studies have largely focused on adults but little is known about spread in children. We determined SARS-CoV-2 seroprevalence in children and adolescents from Arkansas over the first year of the COVID-19 pandemic.Methods We tested remnant serum samples from children from 1–18 years who visited Arkansas hospitals or clinics for non-COVID19-related reasons from April, 2020 through April, 2021 for SARS-CoV-2 antibodies. We used univariable and multivariable regression models to determine association between seropositivity and participant characteristics.Results Among 2400 participants, seroprevalence rose from 7.9% in April/May 2020 (95% CI, 4.9-10.9%) to 25.8% in April 2021 (95% CI, 22.2-29.3%). Hispanic and black children had a significantly higher association with antibody positivity than white children in multiple sampling periods.Conclusions By spring 2021, most children in Arkansas had not been infected with SARS-CoV-2. With the emergence of SARS-CoV-2 variants, recognition of long-term effects of COVID-19, and the lack of an authorized pediatric SARS-CoV-2 vaccine, these results highlight the importance of including children in SARS-CoV-2 public health, clinical care, and research strategies. These findings are important for state and local officials as they consider measures to limit SARS-CoV-2 spread in schools and daycares for the 2021–2022 school year.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by funds from the state of Arkansas through the Coronavirus Aid, Relief, and Economic Security (CARES) Act, the UAMS Time-Sensitive COVID-10 Research Award Program, the UAMS Translational Research Institute (UL1TR000039, TL1TR003109, and UL1TR003107), and the Center for Microbial Pathogenesis and Host Inflammatory Response (P20 GM103625).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All human specimens were obtained with oversight from the UAMS Institutional Review Board (IRB), and waiver of consent and HIPAA applied. The IRB number for the study is 261208.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article.